المؤلفون: Christine M. Bestvina, MD, Jennifer G. Whisenant, PhD, Valter Torri, MD, Alessio Cortellini, MD, Heather Wakelee, MD, Solange Peters, MD, PhD, Elisa Roca, MD, PhD, Alessandro De Toma, MD, Fred R. Hirsch, MD, Hirva Mamdani, MD, Balazs Halmos, MD, Oscar Arrieta, MD, Anne-Cecile Metivier, MD, Mary J. Fidler, MD, Jacobo Rogado, MD, Carolyn J. Presley, MD, MHS, Celine Mascaux, MD, Carlo Genova, MD, PhD, Juan Bautista Blaquier, MD, Alfredo Addeo, MD, Giovanna Finocchiaro, MD, Hina Khan, MD, Julien Mazieres, MD, PhD, Floriana Morgillo, MD, PhD, Jair Bar, MD, Avinash Aujayeb, MBBS, Giannis Mountzios, MD, PhD, Vieri Scotti, MD, Federica Grosso, MD, Erica Geraedts, MD, Ardak N. Zhumagaliyeva, MD, PhD, Leora Horn, MD, Marina Chiara Garassino, MD, Javier Baena, MD

المصدر: JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100335- (2022)

مصطلحات موضوعية: COVID-19, Cancer, Thoracic, NSCLC, TERAVOLT, Registry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364322000595; https://doaj.org/toc/2666-3643

URL الوصول: https://doaj.org/article/40def45b1dee4cd69aa88c393bc82c35

المؤلفون: Sartore-Bianchi A; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; and Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Marsoni S; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; and Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Amatu A; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; and Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Torri V; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; and Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Bonoldi E; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; and Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Bardelli A; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; and Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Trusolino L; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; and Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Siena S; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; and Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jul 30, pp. JCO2400805. Date of Electronic Publication: 2024 Jul 30.

نوع المنشور: Letter

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE